Skip to main content

Rouan Sarah Kathryn's Form 4 filing

Viking Therapeutics, Inc. (VKTX) · filed Oct 25, 2024

Accession no.
0000950170-24-117514
Filed
Oct 25, 2024
Trade date
Oct 25, 2024
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $889.8K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rouan Sarah KathrynCIK 0001761366Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 25, 2024Common Stock, par value $0.00001 per shareMOption exerciseAcquired+11,000$4.88+$53,68011,000Direct
Oct 25, 2024Common Stock, par value $0.00001 per shareSSaleDisposed−11,000$80.89−$889,7900Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 25, 2024Common StockMOption exerciseDisposed−11,000$0.00$011,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)